Palbociclib: all 236 studies that test it

Page 3 of 3. Open to participants first (41), then studies with results posted, then the rest; newest registration first within each.

• Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast CancerStatus unknownNCT02690480Phase 2
• A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast CancerCompletedNCT02684032Phase 1
• National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung CancerCompletedNCT02664935Phase 2
• Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast CancerStatus unknownNCT02626507Phase 1
• Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)Active, not recruitingNCT02605486Phase 1/2
• Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node MetastasesActive, not recruitingNCT02603679Phase 2
• Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast CancerCompletedNCT02599714Phase 1
• A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBCStatus unknownNCT02592746Phase 2
• Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive TumorsActive, not recruitingNCT02592083Phase 2
• "Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment "CompletedNCT02530424Phase 2
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2
• Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast CancerCompletedNCT02448420Phase 2
• Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal WomenCompletedNCT02400567Phase 2
• PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclibCompletedNCT02389842Phase 1
• A Pilot Study To Investigate The Effect Of Concurrent Antacid Administration On The Bioavailability Of Six Experimental Formulations Of PalbociclibCompletedNCT02311946Phase 1
• Study of Palbociclib in MLL-rearranged Acute LeukemiasStatus unknownNCT02310243Phase 1/2
• Effect Of Modafinil And Pioglitazone On The Pharmacokinetics Of Palbociclib (PD-0332991)CompletedNCT02222441Phase 1
• Phase I-II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation and Pharmacokinetics of PD-0332991 in Patients Suffering Metastatic MelanomaStatus unknownNCT02202200Phase 1/2
• Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell LymphomaActive, not recruitingNCT02159755Phase 1
• Study Of Palbociclib (PD-0332991) In Renal ImpairmentCompletedNCT02085538Phase 1
• A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid TumorsCompletedNCT02065063Phase 1
• A Study To Investigate Palbociclib (PD-0332991) Pharmacokinetics In Healthy Subjects Of Japanese Descent Relative To Healthy Non-Asian Subjects, And To Determine If Changes In Palbociclib Dose Result In Proportional Changes In Palbociclib Plasma Exposure In Japanese SubjectsCompletedNCT02059330Phase 1
• Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple MyelomaTerminatedNCT02030483Phase 1
• PALBOCICLIB + PD-0325901 for NSCLC & Solid TumorsCompletedNCT02022982Phase 1
• Randomized Phase II Study to Assess PD 0332991 in Breast CancerCompletedNCT02008734Phase 2
• Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)CompletedNCT01976169Phase 1
• A Study To Investigate The Drug-Drug Interaction Potential Of Rifampin OnThe Investigational Agent Palbociclib (PD-0332991)CompletedNCT01953731Phase 1
• Drug Interaction Study To Investigate The Potential Effect Of Proton Pump Inhibitor On The Pharmacokinetics Of Palbociclib (PD-0332991)CompletedNCT01918176Phase 1
• A Study To Establish The Equivalence Of 2 Palbociclib (PD-0332991) Formulations To The Intended Final Market ProductCompletedNCT01906125Phase 1
• A Drug-Drug Interaction Study To Investigate The Potential For Multiple Doses Of Palbociclib (PD-0332991) To Alter The Pharmacokinetics Of Oral Midazolam In Adult Healthy Women of Non-Childbearing Potential.CompletedNCT01756781Phase 1
• Letrozole and CDK 4/6 Inhibitor for ER Positive, HER2 Negative Breast Cancer in Postmenopausal WomenStatus unknownNCT01709370Phase 2
• Relative Bioavailability StudyCompletedNCT01602887Phase 1
• A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 ExpressionCompletedNCT01536743Phase 2
• PD-0332991, 5-FU, and Oxaliplatin for Advanced Solid Tumor MalignanciesStatus unknownNCT01522989Phase 1
• PD0332991/Paclitaxel in Advanced Breast CancerCompletedNCT01320592Phase 1
• Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell LymphomaTerminatedNCT01111188Phase 1

← Palbociclib overview